Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com

Galectin Therapeutics (NASDAQ:GALT) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Friday, August 16th.

Galectin Therapeutics Trading Down 5.7 %

NASDAQ:GALT opened at $2.66 on Friday. The firm has a 50 day moving average of $2.51 and a 200-day moving average of $2.72. Galectin Therapeutics has a 1 year low of $1.55 and a 1 year high of $4.27. The stock has a market capitalization of $165.66 million, a P/E ratio of -3.59 and a beta of 0.61.

Galectin Therapeutics (NASDAQ:GALT) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). As a group, analysts forecast that Galectin Therapeutics will post -0.79 EPS for the current fiscal year.

Institutional Trading of Galectin Therapeutics

A number of institutional investors have recently bought and sold shares of GALT. Retirement Guys Formula LLC grew its holdings in Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock worth $81,000 after acquiring an additional 12,232 shares during the period. Wealthspire Advisors LLC grew its holdings in shares of Galectin Therapeutics by 116.7% in the 1st quarter. Wealthspire Advisors LLC now owns 398,374 shares of the company’s stock valued at $952,000 after buying an additional 214,512 shares during the period. Vanguard Group Inc. grew its holdings in shares of Galectin Therapeutics by 2.0% in the 1st quarter. Vanguard Group Inc. now owns 1,979,891 shares of the company’s stock valued at $4,732,000 after buying an additional 38,037 shares during the period. Traynor Capital Management Inc. grew its holdings in shares of Galectin Therapeutics by 23.5% in the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after buying an additional 8,164 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Galectin Therapeutics in the 2nd quarter valued at $146,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.